In August, Pfizer halted production of its single-dose vial version of naloxone because of a manufacturing issue it’s been working with the FDA to solve.
Drug experts estimate the shortage will mean about 1 million fewer naloxone doses, which could lead to as many as 18,000 avoidable overdose deaths.
Pfizer expects the shortage to continue through February, according to the report.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
